Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / SILK - Silk Road Medical Reports First Quarter 2023 Financial Results


SILK - Silk Road Medical Reports First Quarter 2023 Financial Results

SUNNYVALE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today reported financial results for the three months ended March 31, 2023.

“2023 is off to a strong start as we execute against our U.S. commercial opportunity, including optimizing and expanding our field presence to meet strong TCAR demand,” said Erica Rogers, CEO of Silk Road Medical. “We also achieved multiple regulatory and product milestones, including the full market release of ENFLATE, our balloon catheter purpose built for TCAR. We continue to execute across our organizational and strategic objectives, setting us up for continued durable growth.”

First Quarter 2023 Financial Results
Revenue for the first quarter of 2023 was $40.1 million, an increase of $12.1 million or 43%, compared to the first quarter of 2022. Growth was driven primarily by growing TCAR adoption.

Gross profit for the first quarter of 2023 was $27.6 million compared to $19.4 million for the first quarter of 2022. Gross margin was 69% for the first quarter of 2023 and 2022. Gross margin in both periods was impacted by production variances.

Operating expenses were $44.5 million for the first quarter of 2023, compared to $35.4 million in the comparable prior year period, which represents an increase of 26%. The increase was driven by increased headcount in our commercial and R&D organizations, along with continued investments in new and ongoing R&D programs.

Net loss was $16.5 million in the first quarter of 2023, or $0.43 per share, as compared to a loss of $16.7 million, or $0.48 per share, in the corresponding period of the prior year.

Cash, cash equivalents and investments were $204.4 million as of March 31, 2023.

2023 Financial Guidance
Silk Road Medical projects revenue for the full year 2023 to range from $176 million to $184 million, which represents 27% to 33% growth over the Company’s prior year revenue.

Conference Call
Silk Road Medical will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, May 9, 2023, to discuss its first quarter 2023 financial results. Those interested in listening to the conference call should register online using this link . Participants are encouraged to register more than 15 minutes before the start of the call. A live and replay version of the webcast will be available at https://investors.silkroadmed.com.

About Silk Road Medical
Silk Road Medical, Inc. (NASDAQ: SILK), is a medical device company located in Sunnyvale, California, and Plymouth, Minnesota, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. For more information on how Silk Road Medical is delivering brighter patient outcomes through brighter clinical thinking, visit www.silkroadmed.com and connect on Twitter, LinkedIn and Facebook.

Forward-Looking Statements
Statements contained in this release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995, including Silk Road Medical’s financial guidance and statements related to the strength of its business and ability to achieve growth. Forward-looking statements are based on current expectations of future events and often can be identified by words such as “expect,” “should,” “project,” “anticipate,” “intend,” “will,” “can,” “may,” “believe,” “could,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Risks and uncertainties may cause Silk Road Medical’s actual results to be materially different than those expressed in or implied by Silk Road Medical’s forward-looking statements. For Silk Road Medical, such risks and uncertainties include, among others, future operating results and financial performance; the ability to obtain an adequate supply of materials and components from its third-party suppliers; product development plans and the ability to commercialize new products in a timely manner; plans to conduct further clinical trials; the ability to obtain additional indications or new regulatory approvals or clearances for its products; use of its products by physicians; the ability to grow its commercialization infrastructure; the effect of economic conditions and COVID-19 or similar pandemics on its business; government and third-party payer coverage and reimbursement; success in retaining and recruiting key personnel; and the ability to obtain and maintain intellectual property protection for its products. More detailed information on these and other factors that could affect Silk Road Medical’s actual results are described in its filings with the U.S. Securities and Exchange Commission, including its most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2023. Silk Road Medical undertakes no obligation to update its forward-looking statements.

Investor Contact:
Lynn Lewis or Marissa Bych
Gilmartin Group
investors@silkroadmed.com

Media:
Michael Fanucchi
Silk Road Medical
mfanucchi@silkroadmed.com

SILK ROAD MEDICAL, INC.
Statements of Operations Data
(unaudited, in thousands, except share and per share data)
Three Months Ended
March 31,
2023
2022
Revenue
$
40,131
$
28,021
Cost of goods sold
12,526
8,577
Gross profit
27,605
19,444
Operating expenses:
Research and development
10,433
8,123
Selling, general and administrative
34,082
27,275
Total operating expenses
44,515
35,398
Loss from operations
(16,910
)
(15,954
)
Interest income
2,287
12
Interest expense
(1,693
)
(621
)
Other income (expense), net
(144
)
(116
)
Net loss
(16,460
)
(16,679
)
Other comprehensive loss:
Change in unrealized gain (loss) on investments, net
249
Net change in other comprehensive loss
249
Net loss and comprehensive loss
$
(16,211
)
$
(16,679
)
Net loss per share, basic and diluted
$
(0.43
)
$
(0.48
)
Weighted average common shares used to compute net loss per share, basic and diluted
38,532,202
35,023,297


SILK ROAD MEDICAL, INC.
Balance Sheets Data
(unaudited, in thousands)
March 31, 2023
December 31, 2022
Assets
Current assets
Cash and cash equivalents
$
50,427
$
55,358
Short-term investments
138,640
158,316
Accounts receivable, net
19,956
18,007
Inventories
17,182
19,293
Prepaid expenses and other current assets
4,049
3,924
Total current assets
230,254
254,898
Long-term investments
15,285
Property and equipment, net
8,897
9,372
Restricted cash
155
155
Other non-current assets
4,996
5,260
Total assets
$
259,587
$
269,685
Liabilities and stockholders' equity
Current liabilities
Accounts payable
$
5,272
$
2,523
Accrued liabilities
15,598
21,965
Total current liabilities
20,870
24,488
Long-term debt
74,848
74,596
Other liabilities
6,256
6,726
Total liabilities
101,974
105,810
Stockholders' equity
Preferred stock, $0.001 par value
Common stock, $0.001 par value
39
38
Additional paid-in capital
517,663
507,715
Accumulated other comprehensive income (loss)
83
(166
)
Accumulated deficit
(360,172
)
(343,712
)
Total stockholders' equity
157,613
163,875
Total liabilities and stockholders' equity
$
259,587
$
269,685

Stock Information

Company Name: Silk Road Medical Inc.
Stock Symbol: SILK
Market: NYSE
Website: silkroadmed.com

Menu

SILK SILK Quote SILK Short SILK News SILK Articles SILK Message Board
Get SILK Alerts

News, Short Squeeze, Breakout and More Instantly...